IRCT20200105046010N35Recruiting未知
In- Vivo Bioequivalence study of Clopidegrel 75 mg Tablets (SANA MED Pharma, Iran) with brand drug (PLAVIX® 75 mg SANOFI, USA) in Iranian healthy volunteers.
SanaMed Co.0 sites24 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 60 years (—)
- Sex
- All
Inclusion Criteria
- •General health
- •Body mass index(18-28)
- •Informed consent
- •Age(18-60)
Exclusion Criteria
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
Investigators
Similar Trials
Not yet recruiting
Unknown
Effect of concomitant use of Clopidogrel with IlaprazoleCTRI/2024/05/067704SRM College of Pharmacy, SRM Institute of Science and Technology
Not yet recruiting
Phase 4
Does the dual antiplatelet medication of aspirin and either clopidogrel or prasugrel affect inflammatory and oxidative stress measures in individuals with acute coronary syndrome similarly?CTRI/2023/07/055349Pt B D Sharma PGIMS Rohtak
Active, not recruiting
Not Applicable
A double blind randomized study of Clopidogrel 75 mg/d versus placebo on a background of ASA 75-100 mg/d, in peripheral disease (PAD) patient receiving a unilateral below knee by-pass graft. - CASPAR 2004MedDRA version: 7.0Level: 1Classification code 10062585EUCTR2004-000822-58-SESanofi-Synthelabo Groupe1,460
Active, not recruiting
Phase 1
A double blind randomized study of Clopidogrel 75 mg/d versus placebo on a background of ASA 75-100 mg/d, in peripheral arterial disease (PAD) patients receiving a unilateral below knee by-pass graft - CASPAR 2004Peripheral arterial diseaseMedDRA version: 7.0Level: 1Classification code 10062585EUCTR2004-000822-58-FIsanofi-synthelabo groupe1,460
Active, not recruiting
Not Applicable
A double-blind, randomized study of clopidogrel 75 mg/d vs placebo,on a background of ASA 75-100 mg/d,in peripheral arterial disease (PAD) patients receiving a unilateral below knee bypass graft.The CASPAR 2004 study(Clopidogrel and Acetyl salicylic acid in bypass Surgery for Peripheral ARterial disease)Treatment of patients with peripheral arterial disease (PAD),already treated with ASA 75-100 mg/d,receiving a unilateral below knee bypass graft.MedDRA version: 6.1Level: PTClassification code 10003604EUCTR2004-000822-58-ITBRISTOL-M.SQUIBB